# MK-8690 PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/mk-8690

> The next catalyst for MK-8690, sponsored by Merck & Co., Inc. (MRK), is its topline data readout, Oct 2027 to Jan 2028.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | MK-8690 |
| Codes | MK-8690, PRA052 |
| Sponsor | Merck & Co., Inc. (MRK) https://sec-api.dev/companies/mrk/catalysts |
| Indications | [Colitis Ulcerative](https://sec-api.dev/indications/colitis-ulcerative), [Rheumatoid Arthritis](https://sec-api.dev/indications/rheumatoid-arthritis) |
| Modality |  |
| FDA designations | none disclosed |

## Timeline

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Colitis Ulcerative; Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07463183 (A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07463183

### Oct 2027 to Jan 2028: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07895524

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Rheumatoid Arthritis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07895524 (A Clinical Trial of MK-8690 in Participants With Rheumatoid Arthritis (MK-8690-004)): Overall Status NOT_YET_RECRUITING; Phase PHASE2; Primary Completion 2027-10-19 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07895524

### October 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 2. Indication: Colitis Ulcerative; Ulcerative Colitis.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT07463183 (A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2027-10-28 (ESTIMATED); Lead Sponsor Merck Sharp & Dohme LLC." https://clinicaltrials.gov/study/NCT07463183

## Same indication

- [AZD1163](https://sec-api.dev/pdufa/azd1163) (AZN)
- [Balinatunfib](https://sec-api.dev/pdufa/balinatunfib) (SNY)
- [BGB-45035](https://sec-api.dev/pdufa/bgb-45035) (ONC)
- [IMVT-1402](https://sec-api.dev/pdufa/imvt-1402) (IMVT)
- [Lutikizumab](https://sec-api.dev/pdufa/lutikizumab) (ABBV)
- [LY3541860](https://sec-api.dev/pdufa/ly3541860) (LLY)
- [LY3871801](https://sec-api.dev/pdufa/ly3871801) (LLY)
- [Natrunix 400 mg](https://sec-api.dev/pdufa/natrunix) (XBIT)
- [PTC844](https://sec-api.dev/pdufa/ptc844) (PTCT)
- [SAR441566](https://sec-api.dev/pdufa/sar441566) (SNY)
- [SAR443122](https://sec-api.dev/pdufa/sar443122) (SNY)
- [SPY002-072](https://sec-api.dev/pdufa/spy002-072) (SYRE)

Calendar months: [October 2027](https://sec-api.dev/fda-calendar/2027-10)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/mk-8690.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MK-8690 PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/mk-8690

```bibtex
@misc{secapidev_pdufa_mk_8690_20261116,
  title        = {MK-8690 PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/mk-8690}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_mk_8690_20261116","title":"MK-8690 PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/mk-8690","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
